<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">RADES, DIRK</style></author><author><style face="normal" font="default" size="100%">WARWAS, BRITTA</style></author><author><style face="normal" font="default" size="100%">CREMERS, FLORIAN</style></author><author><style face="normal" font="default" size="100%">GERULL, KARSTEN</style></author><author><style face="normal" font="default" size="100%">PRIES, RALPH</style></author><author><style face="normal" font="default" size="100%">LEICHTLE, ANKE</style></author><author><style face="normal" font="default" size="100%">BRUCHHAGE, KARL L.</style></author><author><style face="normal" font="default" size="100%">HAKIM, SAMER G.</style></author><author><style face="normal" font="default" size="100%">SCHILD, STEVEN E.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The First Prognostic Tool to Estimate the Risk of Late Grade ≥3 Xerostomia in Patients Irradiated for Head-and-Neck Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">3035-3039</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.15789</style></doi><volume><style face="normal" font="default" size="100%">42</style></volume><issue><style face="normal" font="default" size="100%">6</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Xerostomia is a serious complication following radiotherapy of head-and-neck cancers. A prognostic tool was developed for estimating its risk. Patients and Methods: In our previous study, age, tumor site, bilateral lymph node involvement, definitive radiotherapy, and addition of systemic therapies showed significant associations with grade ≥3 late xerostomia or trends. In additional analyses, mean radiation dose to ipsilateral parotid gland was significant (p=0.011). These six factors were included in the prognostic tool. Scoring points of 0 (lower risk) or 1 (higher risk) were assigned to each factor and added for each patient. Results: Patient scores ranged between 0 and 6; Grade ≥3 xerostomia rates were 0%, 8%, 24%, 26%, 25%, 42%, and 100%, respectively. Three groups were designed (0-1, 2-4, and 5-6 points) with grade ≥3 xerostomia rates of 5%, 25%, and 50%, respectively (p&lt;0.001). Conclusion: This new tool helps estimating the risk of radiation-induced grade ≥3 xerostomia. It can support physicians and other medical staff members during treatment planning.</style></abstract></record></records></xml>